Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.58. Xtant Medical shares last traded at $0.55, with a volume of 7,882 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the company a "buy" rating in a report on Friday.
Get Our Latest Stock Analysis on XTNT
Xtant Medical Price Performance
The stock has a market capitalization of $71.81 million, a P/E ratio of -27.56 and a beta of 0.35. The company has a quick ratio of 1.01, a current ratio of 2.44 and a debt-to-equity ratio of 0.49.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). Xtant Medical had a negative net margin of 3.00% and a negative return on equity of 6.71%. The company had revenue of $29.94 million for the quarter.
Institutional Trading of Xtant Medical
An institutional investor recently bought a new position in Xtant Medical stock. Juniper Investment Company LLC bought a new stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 348,399 shares of the medical device company's stock, valued at approximately $408,000. Xtant Medical makes up 0.2% of Juniper Investment Company LLC's portfolio, making the stock its 10th largest position. Juniper Investment Company LLC owned approximately 0.27% of Xtant Medical as of its most recent SEC filing. Institutional investors own 69.33% of the company's stock.
Xtant Medical Company Profile
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
